
Record of Telephone Conversation, October 26, 2012 - Flucelvax


 

Submission Type: BLA    Submission ID: 125408/0    Office: OVRR

Product:

Influenza Virus Vaccine

Applicant:

Novartis Vaccines and Diagnostics, Inc.

Telecon Date/Time: 26-Oct-2012 04:30 PM        Initiated by FDA? Yes

Telephone Number:

Communication Categorie(s):

1. Advice

 

Author: TIMOTHY NELLE

Telecon Summary:

Package Insert Changes for 20113-14 Influenza Season

FDA Participants: Timothy Nelle

Non-FDA Participants: Matthew Gollwitzer

Trans-BLA Group: No

 

Related STNs: None

Related PMCs: None

Telecon Body:

During this telecon, Novartis agreed to make the following suggested edits in the FLUCELVAX package insert for next years influenza season. 

 
1.Under Section 8.5 Geriatric Use, the total number of subjects (currently list as 6711) includes subjects from the site 2 of the lot consistency study which should be removed.  Please change the total number of subjects to 6281, as it is listed in Section 6.1, and adjust the percentage (numbers) in the same sentence as needed.

 
2.At the top of Table 5, please indicate the total number of subjects for the 18 through 49 Years column and the 50 through 64 Years column.

 
3.The residual amount of BPL was not listed correctly in the current version of the PI.  It should be listed as ------(b)(4)------------ instead of less than or equal to 0.5 mcg.
